Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO

Core Viewpoint - Agios Pharmaceuticals, Inc. is under investigation for potential violations of federal securities laws following the mixed results of its RISE UP Phase 3 trial for Mitapivat in Sickle Cell Disease, which led to a significant drop in its stock price [1]. Group 1: Trial Results - On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial, which met one primary endpoint but failed to achieve a statistically significant improvement in the annualized rate of pain crises [1]. - The key secondary endpoint, which was the change from baseline in PROMIS Fatigue, was also not met [1]. Group 2: Stock Price Impact - Following the trial results, Agios' stock price fell by $22.33 per share, opening at $23.16 per share [1].